Clinicians can soon offer women the convenience of an extended-cycle oral contraceptive (OC). The FDA recently approved levonorgestrel/ethinyl estradiol (Seasonale, Barr Laboratories) 0.15 mg/0.03 mg tablets for the prevention of pregnancy. The manufacturer plans a November 1 launch for Seasonale, the first extended-cycle OC to receive FDA approval.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.